{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T17:35:26Z","timestamp":1786642526945,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":52,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"DOI":"10.1186\/s12887-026-07118-5","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T01:57:08Z","timestamp":1782093428000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neurological adverse events of blinatumomab in children with B-cell acute lymphoblastic leukemia: a retrospective study"],"prefix":"10.1186","volume":"26","author":[{"given":"Yuan-Yuan","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Jun","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"issue":"3","key":"7118_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"10230","key":"7118_CR2","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/S0140-6736(19)33018-1","volume":"395","author":"F Malard","year":"2020","unstructured":"Malard F, Mohty M. Acute lymphoblastic leukaemia. Lancet. 2020;395(10230):1146\u201362.","journal-title":"Lancet"},{"issue":"7","key":"7118_CR3","first-page":"1","volume":"16","author":"Minimal","year":"2016","unstructured":"Minimal. Residual disease evaluation in childhood acute lymphoblastic leukemia: a clinical evidence review. Ont Health Technol Assess Ser, 2016. 16(7): pp. 1\u201352.","journal-title":"Ont Health Technol Assess Ser"},{"issue":"8","key":"7118_CR4","doi-asserted-by":"publisher","first-page":"e29715","DOI":"10.1002\/pbc.29715","volume":"69","author":"F Locatelli","year":"2022","unstructured":"Locatelli F, et al. Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high-risk first relapse B-cell precursor acute lymphoblastic leukemia. Pediatr Blood Cancer. 2022;69(8):e29715.","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"7118_CR5","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1200\/JCO.23.01392","volume":"42","author":"A Hodder","year":"2024","unstructured":"Hodder A, et al. Blinatumomab for first-line treatment of children and young persons with B-ALL. J Clin Oncol. 2024;42(8):907\u201314.","journal-title":"J Clin Oncol"},{"issue":"3","key":"7118_CR6","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1182\/bloodadvances.2021005579","volume":"6","author":"F Locatelli","year":"2022","unstructured":"Locatelli F, et al. Blinatumomab in pediatric relapsed\/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis. Blood Adv. 2022;6(3):1004\u201314.","journal-title":"Blood Adv"},{"issue":"9","key":"7118_CR7","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1001\/jama.2021.0669","volume":"325","author":"PA Brown","year":"2021","unstructured":"Brown PA, et al. Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2021;325(9):833\u201342.","journal-title":"JAMA"},{"issue":"9","key":"7118_CR8","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2021.0987","volume":"325","author":"F Locatelli","year":"2021","unstructured":"Locatelli F, et al. Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA. 2021;325(9):843\u201354.","journal-title":"JAMA"},{"issue":"1","key":"7118_CR9","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1182\/hematology.2019000017","volume":"2019","author":"A Winters","year":"2019","unstructured":"Winters A, Gore L. Moving immunotherapy into the front line in ALL. Hematol Am Soc Hematol Educ Program. 2019;2019(1):209\u201317.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"5","key":"7118_CR10","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1111\/bjh.18314","volume":"198","author":"DK Yeoh","year":"2022","unstructured":"Yeoh DK, Blyth CC, Kotecha RS. Blinatumomab as bridging therapy in paediatric B-cell acute lymphoblastic leukaemia complicated by invasive fungal disease. Br J Haematol. 2022;198(5):887\u201392.","journal-title":"Br J Haematol"},{"issue":"6","key":"7118_CR11","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1159\/000525835","volume":"145","author":"H Goto","year":"2022","unstructured":"Goto H, et al. Safety and efficacy of blinatumomab in Japanese adult and pediatric patients with relapsed\/refractory B-cell precursor acute lymphoblastic leukemia: final results from an expansion cohort. Acta Haematol. 2022;145(6):592\u2013602.","journal-title":"Acta Haematol"},{"issue":"9","key":"7118_CR12","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1111\/jcpt.13741","volume":"47","author":"P Mocquot","year":"2022","unstructured":"Mocquot P, et al. The pharmacology of blinatumomab: state of the art on pharmacodynamics, pharmacokinetics, adverse drug reactions and evaluation in clinical trials. J Clin Pharm Ther. 2022;47(9):1337\u201351.","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"7118_CR13","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12916-025-03913-6","volume":"23","author":"W Gao","year":"2025","unstructured":"Gao W, et al. Adverse events in the nervous system associated with blinatumomab: a real-world study. BMC Med. 2025;23(1):72.","journal-title":"BMC Med"},{"key":"7118_CR14","unstructured":"Amgen Inc. BLINCYTO (blinatumomab) injection, powder for solution for intravenous use: full prescribing information. 2025. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/125557s032lbl.pdf."},{"issue":"7","key":"7118_CR15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41408-020-00342-x","volume":"10","author":"F Locatelli","year":"2020","unstructured":"Locatelli F, et al. Blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study. Blood Cancer J. 2020;10(7):77.","journal-title":"Blood Cancer J"},{"issue":"11","key":"7118_CR16","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","volume":"127","author":"A Viardot","year":"2016","unstructured":"Viardot A, et al. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma. Blood. 2016;127(11):1410\u20136.","journal-title":"Blood"},{"issue":"1","key":"7118_CR17","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","volume":"16","author":"MS Topp","year":"2015","unstructured":"Topp MS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16(1):57\u201366.","journal-title":"Lancet Oncol"},{"issue":"4","key":"7118_CR18","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transpl. 2019;25(4):625\u201338.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"6","key":"7118_CR19","doi-asserted-by":"publisher","first-page":"e1576","DOI":"10.1002\/wsbm.1576","volume":"14","author":"T Gu","year":"2022","unstructured":"Gu T, et al. Mechanisms of immune effector cell-associated neurotoxicity syndrome after CAR-T treatment. WIREs Mech Dis. 2022;14(6):e1576.","journal-title":"WIREs Mech Dis"},{"issue":"5","key":"7118_CR20","doi-asserted-by":"publisher","first-page":"E113","DOI":"10.1002\/ajh.26880","volume":"98","author":"BJ Lee","year":"2023","unstructured":"Lee BJ, et al. Timing of intrathecal chemotherapy and blinatumomab impacts neurotoxicity in acute lymphoblastic leukemia. Am J Hematol. 2023;98(5):E113\u20135.","journal-title":"Am J Hematol"},{"issue":"6","key":"7118_CR21","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1177\/10434542211040203","volume":"38","author":"EK Browne","year":"2021","unstructured":"Browne EK, et al. Evidence-based recommendations for nurse monitoring and management of immunotherapy-induced cytokine release syndrome: a systematic review from the children\u2019s oncology group. J Pediatr Oncol Nurs. 2021;38(6):399\u2013409.","journal-title":"J Pediatr Oncol Nurs"},{"issue":"1","key":"7118_CR22","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00277-018-3497-0","volume":"98","author":"AS Stein","year":"2019","unstructured":"Stein AS, et al. Neurologic adverse events in patients with relapsed\/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors. Ann Hematol. 2019;98(1):159\u201367.","journal-title":"Ann Hematol"},{"issue":"1","key":"7118_CR23","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s11684-021-0835-8","volume":"16","author":"S Wang","year":"2022","unstructured":"Wang S, et al. Preclinical characterization and comparison between CD3\/CD19 bispecific and novel CD3\/CD19\/CD20 trispecific antibodies against B-cell acute lymphoblastic leukemia: targeted immunotherapy for acute lymphoblastic leukemia. Front Med. 2022;16(1):139\u201349.","journal-title":"Front Med"},{"issue":"4","key":"7118_CR24","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s40262-019-00823-8","volume":"59","author":"JD Clements","year":"2020","unstructured":"Clements JD, et al. Population pharmacokinetics of blinatumomab in pediatric and adult patients with hematological malignancies. Clin Pharmacokinet. 2020;59(4):463\u201374.","journal-title":"Clin Pharmacokinet"},{"issue":"26","key":"7118_CR25","doi-asserted-by":"publisher","first-page":"6226","DOI":"10.1182\/blood-2012-01-400515","volume":"119","author":"M Klinger","year":"2012","unstructured":"Klinger M, et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19\/CD3-bispecific BiTE antibody blinatumomab. Blood. 2012;119(26):6226\u201333.","journal-title":"Blood"},{"issue":"3","key":"7118_CR26","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41419-020-2388-1","volume":"11","author":"L Li","year":"2020","unstructured":"Li L, et al. Treatment response, survival, safety, and predictive factors to chimeric antigen receptor T cell therapy in Chinese relapsed or refractory B cell acute lymphoblast leukemia patients. Cell Death Dis. 2020;11(3):207.","journal-title":"Cell Death Dis"},{"issue":"Supplement 1","key":"7118_CR27","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1182\/blood-2023-187295","volume":"142","author":"T Kewan","year":"2023","unstructured":"Kewan T, et al. CAR T-related toxicities based on dynamic proteomic profiles identifies risk factors for Cytokine Release Syndrome (CRS) and Immune Effector Cell -Associated Neurotoxicity Syndrome (ICANS). Blood. 2023;142(Supplement 1):2132\u20132132.","journal-title":"Blood"}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12887-026-07118-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-026-07118-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-026-07118-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T17:01:41Z","timestamp":1786640501000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12887-026-07118-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7118"],"URL":"https:\/\/doi.org\/10.1186\/s12887-026-07118-5","relation":{},"ISSN":["1471-2431"],"issn-type":[{"value":"1471-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"assertion":[{"value":"15 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Children\u2019s Hospital of Nanjing Medical University Research Ethics Committee (202602037-1). All procedures performed were in accordance with the ethical standards of the institutional research committee and with the Declaration of Helsinki. The need for informed consent was waived by the ethics committee due to the retrospective nature of the study. Details that might disclose the identity of the subjects have been omitted.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"746"}}